[HTML][HTML] The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
M Grymonprez, M Petrovic… - Thrombosis and …, 2024 - thieme-connect.com
Background Polypharmacy may affect outcomes in patients with atrial fibrillation (AF) using
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …
[HTML][HTML] The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
M Grymonprez, M Petrovic, TL De Backer… - Thrombosis and …, 2024 - ncbi.nlm.nih.gov
Background Polypharmacy may affect outcomes in patients with atrial fibrillation (AF) using
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …
The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
M Grymonprez, M Petrovic, T De Backer… - THROMBOSIS AND …, 2024 - biblio.ugent.be
Background: Polypharmacy may affect outcomes in patients with atrial fibrillation (AF) using
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …
[PDF][PDF] The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
M Grymonprez, M Petrovic, TL De Backer, S Steurbaut… - 2023 - researchportal.vub.be
Background Polypharmacy may affect outcomes in patients with atrial fibrillation (AF) using
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …
[PDF][PDF] The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
M Grymonprez, M Petrovic, TL De Backer, S Steurbaut… - 2023 - researchgate.net
Background Polypharmacy may affect outcomes in patients with atrial fibrillation (AF) using
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …
The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.
M Grymonprez, M Petrovic, TL De Backer… - Thrombosis and …, 2023 - europepmc.org
Background Polypharmacy may affect outcomes in patients with atrial fibrillation (AF) using
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …
The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
M Grymonprez, M Petrovic… - Thrombosis and …, 2024 - pubmed.ncbi.nlm.nih.gov
Background Polypharmacy may affect outcomes in patients with atrial fibrillation (AF) using
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …
The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
M Grymonprez, M Petrovic… - Thrombosis and …, 2024 - researchportal.vub.be
BACKGROUND: Polypharmacy may affect outcomes in patients with atrial fibrillation (AF)
using non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists …
using non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists …
[PDF][PDF] The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
M Grymonprez, M Petrovic, TL De Backer, S Steurbaut… - 2023 - researchgate.net
Background Polypharmacy may affect outcomes in patients with atrial fibrillation (AF) using
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …
The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.
M Grymonprez, M Petrovic, TL De Backer… - Thrombosis and …, 2023 - europepmc.org
Background Polypharmacy may affect outcomes in patients with atrial fibrillation (AF) using
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …